Genfit S.A.

Genfit reported 2021 revenue and other operating income of €85.6 million, up from €7.8 million in 2020. Operating expenses were €53.8 million, down from €90.7 million a year earlier, leading to consolidated operating income of €31.8 million versus an operating loss of €82.9 million in 2020. Net profit was €67.3 million after €2.2 million of corporate income tax expense, compared with a net loss of €101.2 million in 2020. Cash and cash equivalents were €258.8 million at December 31, 2021, and total financial debt declined to €74.2 million from €185.7 million. For 2022, management said cash used in operating activities is expected to increase to €65 million, with up to €30 million of payments in the first half related to VAT and corporate tax tied to the Ipsen upfront. The company also said it expects ELATIVE top-line data in Q2 2023, first hepatic impairment results for NTZ as early as Q3 2022, renal impairment data in Q4 2022, and a Phase 1b/2 study for GNS5611 toward the end of 2022.

Pascal Prigent framed 2021 as a pivotal turnaround year after the disappointment in NASH, saying Genfit executed on three priorities: improving the balance sheet, advancing remaining lead programs, and building a more diversified pipeline. He emphasized that the Ipsen partnership and debt renegotiation gave the company much greater financial visibility and flexibility, including future milestone and royalty potential. His tone was constructive and forward-looking, with repeated focus on optionality, diversification, and the ability to keep investing in R&D.

Tom Baetz said the 2021 numbers were heavily shaped by the €120 million Ipsen upfront, of which €80 million was recognized as revenue and €40 million deferred. He highlighted a major cost reset: operating expenses fell to €53.8 million from €90.7 million, including reduced R&D, D&A, marketing, and other expenses, and one-time restructuring costs fell to €0.1 million from €5.3 million. He also detailed the balance-sheet cleanup, noting convertible debt was reduced and its maturity extended to October 2025, financial interest expense dropped to €4.8 million from €11.6 million, and the company ended with €258.8 million in cash and cash equivalents. He guided to up to €30 million of first-half 2022 outflows tied to taxes/VAT and €65 million of operating cash use in 2022, excluding future business development.

Analysts pressed management on business development appetite, especially whether Genfit wants early-stage or clinical-stage assets. Pascal Prigent said the company is looking for both, but wants at least one clinical-stage deal if the data are compelling, and specifically aims to build complementary mechanisms for ACLF. Questions on NTZ timing and proof-of-concept led Carol Addy to say the current Phase 1 work is to position the asset for IND submission and a future proof-of-concept study, with initiation planned before the end of Q1 2023, but it is too early to give a detailed timeline before FDA discussions. On NIS4, management said it is not seeing a meaningful near-term commercial market until a NASH drug is approved, but NIMBLE data strengthened the platform technically and should help drive future adoption once the market forms.